Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04KYB
|
|||
| Former ID |
DIB007838
|
|||
| Drug Name |
ASCJ-9
|
|||
| Synonyms |
Dimethylcurcumin; ASC-JMX1; ASCJ-9; ASCJ-9 (systemic), AndroScience; ASCJ-9 (topical), AndroScience; Androgen antagonist (alopecia/acne), AndroScience; Androgen receptor degradation enhancers (oral, spinal bulbar muscular atrophy), AndroScience
Click to Show/Hide
|
|||
| Indication | Acne vulgaris [ICD-11: ED80; ICD-10: L70.0; ICD-9: 706.1] | Phase 2 | [1] | |
| Alopecia [ICD-11: ED70; ICD-9: 704.09] | Phase 2 | [2] | ||
| Company |
AndroScience
|
|||
| Structure |
 |
Download2D MOL |
||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT01289574) Topical ASC-J9 Cream for Acne. U.S. National Institutes of Health. | |||
| REF 3 | Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis. 2013 Aug 8;4:e764. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.